Skip to main content

Commodification of Care

  • Living reference work entry
  • First Online:
Encyclopedia of Business and Professional Ethics
  • 147 Accesses

Synonyms

Big Pharma; Corporate greed; Health; Immoralities; Medical industry

Introduction

This article considers the trend of powerful entities that are in full control of the means and knowledge needed to provide care and assistance to those who need it most. The article specifically focuses on healthcare, since the healthcare industry could be considered the strongest and most solid manifestation of care commodification. Scholars on the topic of healthcare and the ethics surrounding this important aspect in our lives have questioned whether healthcare could be considered a commodity as any other. More importantly, the question was raised, whether free-market ethic could work for healthcare. An often cited perspective since the early questioning has been that healthcare is not a commodity as any other because, (1) healthcare happens in a physician-patient relationship, which clearly differs from the usual definition of a commodity as being a transaction without relationship between...

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Institutional subscriptions

References

  • Applbaum K (2009) Marketing global healthcare: the practices of big pharma. In: Panitch L, Leys C (eds) The socialist register 2010: morbid symptoms: health under capitalism. Merlin Press and Monthly Review, London, pp 84–102

    Google Scholar 

  • Brown S, McDonagh P, Shultz C (2012) Dark marketing: ghost in the machine or skeleton in the cupboard? Eur Bus Rev 24(3):196–215

    Article  Google Scholar 

  • Chih-Han Huang E, Pu C, Chou Y, Huang N (2018) Public trust in physicians—healthcare commodification as a possible deteriorating factor: cross-sectional analysis of 23 countries. INQUIRY J Healthcare Organ Prov Financ 55:1–11

    Google Scholar 

  • Christiansen I (2017) Commodification of healthcare and its consequences. World Rev Polit Econ 8(1):82–103

    Article  Google Scholar 

  • D’Agostino G (2012) Challenges to the patent system. Intellect Prop J 25(1):57–74

    Google Scholar 

  • Davis K, Stremikis K, Squires D, Schoen C (2014) Mirror, mirror on the wall: how the performance of the U.S. healthcare system compares internationally. The Commonwealth Fund. Accessed May 7, 2019 at http://www.commonwealthiund.org/publications/iundreports/2010/jun/mirror-mirror-update

  • Goldman D (2015, December 18) Who is Martin Shkreli? A timeline. CNN Money. Retrieved from http://money.cnn.com/2015/12/18/news/companies/martin-shkreli/

  • Gottschalk M (2009) US health reform and the Stockholm syndrome. In: Panitch L, Leys C (eds) Socialist register, 2010. Morbid symptoms: health under capitalism. Merlin Press and Monthly Review Press, London, pp 103–124

    Google Scholar 

  • Leys C (2009) Health, healthcare and capitalism. In: Panitch L, Leys C (eds) Socialist register, 2010. Morbid symptoms: health under capitalism. Merlin Press and Monthly Review, London, pp 1–28

    Google Scholar 

  • Mangan D (2017, March 3) Mylan CEO Heather Bresch says diversification is boosting company after EpiPen controversy. CNBC: Biotech and Pharmaceuticals. Retrieved from http://www.cnbc.com/2017/03/03/mylan-ceo-heather-bresch-discusses-epipen-controversy.html

  • Martin Shkreli and the Increased Cost of Daraprim (2015) Penn Bioethics J 11(2):6

    Google Scholar 

  • Oppenheimer M, Lavan H, Martin WF (2015) A framework for understanding ethical and efficiency issues in pharmaceutical intellectual property litigation. J Bus Ethics 132(3):505–524

    Article  Google Scholar 

  • Orozco D, Poonamallee L (2014) The role of ethics in the commercialization of indigenous knowledge. J Bus Ethics 119(2):275–286

    Article  Google Scholar 

  • Ossola A (2016, August 26) What you need to know about the EpiPen. Why is everyone talking about an injector? Popular Science: Health. Retrieved from http://www.popsci.com/what-are-epipens

  • Pellegrino ED (1999) The commodification of medical and healthcare: the moral consequences of a paradigm shift from a professional to a market ethic. J Med Philos 24:243–266

    Article  Google Scholar 

  • Phipps FM (2016) Global health for the 21st century and beyond. Int J Health Gov 21(4):263–267

    Article  Google Scholar 

  • Reddy M, Mythri S (2016) Health-care ethics and the free market value system. Indian J Psychol Med 38(5):371–375

    Article  Google Scholar 

  • Smythe C (2015, December 17) Shkreli, drug price gouger, denies fraud and posts bail arrested Thursday, accused of Ponzi-like scheme. Bloomberg. Retrieved from https://www.bloomberg.com/features/2015-martin-shkreli-securities-fraud/

  • Turtle B (2016, September 21) Why the EpiPen Price scandal sums up everything we hate about big Business & Politics. Time.Com. Retrieved from http://time.com/money/4502891/epipen-pricing-scandal-big-pharma-politics/

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joan Marques .

Editor information

Editors and Affiliations

Section Editor information

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Marques, J., Coffman, M. (2020). Commodification of Care. In: Poff, D., Michalos, A. (eds) Encyclopedia of Business and Professional Ethics. Springer, Cham. https://doi.org/10.1007/978-3-319-23514-1_1183-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-23514-1_1183-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-23514-1

  • Online ISBN: 978-3-319-23514-1

  • eBook Packages: Religion and PhilosophyReference Module Humanities and Social SciencesReference Module Business, Economics and Social Sciences

Publish with us

Policies and ethics